<DOC>
	<DOCNO>NCT02737891</DOCNO>
	<brief_summary>Safety Efficacy Study Tesofensine/Metoprolol Treatment Subjects With Type 2 Diabetes Mellitus</brief_summary>
	<brief_title>Safety Efficacy Study Tesofensine/Metoprolol Treatment Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This double-blind , randomize , placebo-controlled , multiple-dose , two-center , safety efficacy study co-administration tesofensine/metoprolol treatment subject T2DM . Study medication administer ninety ( 90 ) day ( +2 day final assessment half-dose metoprolol ) . Following baseline assessment , eligible subject randomly assign one two arm ( 1:1 ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<criteria>1 . Males females 2 . Confirmed diagnosis T2DM 3 . 1870 year age 4 . HbA1c â‰¥7.0 % 1 . Hypersensitivity tesofensine/metoprolol 2 . Heart failure class II great accord New York Heart Association ( NYHA ) decompensated heart failure 3 . History myocardial infarction stroke within 12 month prior enrolment 4 . History coronary revascularisation angioplasty last 12 month prior enrolment 5 . Patients report angina last 6 month prior enrolment 6 . Treatment insulin and/or injectable antidiabetic medication , TZDs 7 . Any clinically significant cardiac arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>